Barclays initiated coverage of Schrodinger (SDGR) with an Overweight rating and $25 price target The firm sees two “value-inflecting” data readouts for the company Q4. Schrodinger will announce initial Phase 1 data for SGR- 2921 and for SGR-3515 in advanced solid tumors, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SDGR:
- Schrodinger’s Strong Financial Performance and Promising Pipeline Developments Justify Buy Rating
- Schrodinger’s Strategic Growth and Financial Stability: Buy Rating Affirmed
- Schrodinger, Inc. Earnings Call: Growth Amid Challenges
- Schrödinger, Inc. Reports Strong Q2 2025 Results
- Schrodinger reports Q2 EPS (59c), one estimate (64c)